Ghana vs Suriname: Access to anti-retroviral drugs, male
Ghana
40.0%
in 2024
Suriname
41.0%
in 2024
Ghana rank
131st
Suriname rank
130th
Access to anti-retroviral drugs, male over time
- Ghana
- Suriname
How they compare
Suriname currently reports 41.0% against 40.0% in Ghana, a difference of 1.0%.
The two have swapped places 4 times across 25 shared years of data; in 2000 it was Suriname ahead.
Ghana ranks 131st and Suriname ranks 130th of 141 countries.
Suriname has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Ghana | Suriname | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 3.3% | 5.6% | 2.3% | Suriname |
| 2010s | 22.2% | 25.2% | 3.0% | Suriname |
| 2020s | 35.2% | 37.6% | 2.4% | Suriname |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Ghana or Suriname?
- Suriname, at 41.0% against 40.0% in Ghana as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Ghana and Suriname?
- 1.0%, with Suriname ahead.
- How many years of comparable data are there for Ghana and Suriname?
- 25 years are reported by both, from 2000 to 2024.
- How do Ghana and Suriname rank globally for access to anti-retroviral drugs, male?
- Ghana ranks 131st and Suriname ranks 130th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.